

Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P4747USW	SERIAL NO. 10/502,255
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		APPLICANT Alvaro et al.	
		FILING DATE 28 March 2005	GROUP 1024

## U.S. PATENT DOCUMENTS


Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No
ZT	1	EP-1 328 632-A	07-18-2003	EP		
ZT	2	WO-04 091624-A	10-28-2004	WO		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

ZT	3	GIARDINA G.A.M., ET AL.; Recent advances in neurokinin-3 receptor antagonists.: Expert Opinion On Therapeutic Patents; 2000; 10(6); 639-660; Ashley Publications; G8				

Examiner Signature		Date Considered	24 AUGUST 2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Sheet 1 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PI4747USW	SERIAL NO. 10/502,265
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Alvaro et al.	
		FILING DATE March 28, 2005	GROUP <del>1625</del> 1624

## U.S. PATENT DOCUMENTS


Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

ZT	1	Acute Stress Disorder; Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); 2000; Fourth Edition; pages 468-472; American Psychiatric Association; Washington, DC, USA					
ZT	2	Anxiety Disorders; Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); 2000; Fourth Edition; 428-30; American Psychiatric Association; Washington, DC, USA					
ZT	3	ARGYROPOULOS, ET AL.; Exp. Opin. Invest. Drugs; 2000; 9/6; 1871-1875;					
ZT	4	BALLARD, ET AL.; European Journal of Pharmacology; 2001; 412; 255-284;					
ZT	5	KRAMER ET AL.; Science; 1998; 281; 1640-1645;					
ZT	6	SCRIMA, ET AL.; Biol Psychiatry; 1988; 28; 331-343;					

Examiner Signature		Date Considered	7 SEPTEMBER 2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PI4747USW	SERIAL NO. 10/502,255
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Alvaro et al.	GROUP <del>1623</del> 1624
		FILING DATE March 28, 2005	

## U.S. PATENT DOCUMENTS


Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

BT 7	Sleep disorders; Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); 2000; Fourth Edition; 597-681; American Psychiatric Association; Washington, DC, USA

Examiner Signature 	Date Considered 7 SEPTEMBER 2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	